Novo Nordisk's pricing approaches in the U.S. have drawn sharp criticism from lawmakers like Senator Sanders, that has accused the company of value gouging, mentioning the stark contrast amongst U.S. rates and those in Europe and copyright.Novo Nordisk is linked to governing administration funded collaborative research initiatives with other indust